All In Biotech

Drug Trial Radar · NCT06519591

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 25, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.

Conditions

  • Gastric Cancer Stage IV
  • Peritoneal Metastases

Interventions

  • Cadonilimab, LM-302, S-1, paclitaxelDrug

    Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1-year survival rateTime frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Huangpu District, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.